Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Apr 21, 2016 6:00pm

105 Views

Post# 24796355

RE:RE:RE:SIX POINT DROP/ PRESENTATION YESTERDAY????

Agreed. It will happen. I'm just pleased that DM recognized the need and I am pleased that it is happening now.

To me it is a signal that the very positive news and potential for apabetalone (rvx-208) as well as the orphan trials and also the zen3694 prostate trial needs to be communicated to key target markets.

I believe (and I think that most investors feel) the share price is grossly low. The value is not being perceived for a compound that is in a phase 3 trial.

Some of the misinformation (as pointed out by BDAZ) about rvx-208 by competitors needs to be corrected and RVX has now made the move to deal with this.

So, bottom line for me, is that momentum is building.
Cheers
Toinv

Bullboard Posts

A junior copper-gold stock trading at a bargain of monumental proportions